Molecularly targeted therapies for metastatic triple-negative breast cancer

Soley Bayraktar, Stefan Glück

Research output: Contribution to journalArticle

90 Citations (Scopus)

Abstract

Triple-negative breast cancer (TNBC) refers to a heterogeneous group of tumors that do not express the estrogen/progesterone-receptor (ER/PR), and human epidermal growth factor receptor-2 (HER2). TNBC is an aggressive histological subtype with limited treatment options and very poor prognosis following progression after standard chemotherapy regimens. There have been significant improvements in the outcome of other subtypes of breast cancer, including ER-positive/HER2 overexpressed tumors, attributed to the addition of targeted therapy, including hormonal agents and trastuzumab. However, no specific targeted agents are currently available for the treatment of TNBC. This review aims to collate and describe the most recent data on targeted therapies that have demonstrated efficacy in the management of metastatic TNBC. Targeted agents that have been investigated in the treatment of metastatic TNBC include inhibitors of poly(ADP-ribose) polymerase, angiogenesis, mammalian target of rapamycin, epidermal growth factor receptor, HDAC, Jak2, and Src. Several of these agents have shown considerable promise.

Original languageEnglish
Pages (from-to)21-35
Number of pages15
JournalBreast Cancer Research and Treatment
Volume138
Issue number1
DOIs
StatePublished - Feb 11 2013
Externally publishedYes

Fingerprint

Triple Negative Breast Neoplasms
Therapeutics
Progesterone Receptors
Sirolimus
Epidermal Growth Factor Receptor
Estrogen Receptors
Neoplasms
Breast Neoplasms
Drug Therapy

Keywords

  • EGFR
  • Metastatic
  • PARP
  • Targeted agents
  • Triple-negative breast cancer
  • VEGFR

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Molecularly targeted therapies for metastatic triple-negative breast cancer. / Bayraktar, Soley; Glück, Stefan.

In: Breast Cancer Research and Treatment, Vol. 138, No. 1, 11.02.2013, p. 21-35.

Research output: Contribution to journalArticle

Bayraktar, Soley ; Glück, Stefan. / Molecularly targeted therapies for metastatic triple-negative breast cancer. In: Breast Cancer Research and Treatment. 2013 ; Vol. 138, No. 1. pp. 21-35.
@article{31609781b29a4c98938cc9659ef5ec97,
title = "Molecularly targeted therapies for metastatic triple-negative breast cancer",
abstract = "Triple-negative breast cancer (TNBC) refers to a heterogeneous group of tumors that do not express the estrogen/progesterone-receptor (ER/PR), and human epidermal growth factor receptor-2 (HER2). TNBC is an aggressive histological subtype with limited treatment options and very poor prognosis following progression after standard chemotherapy regimens. There have been significant improvements in the outcome of other subtypes of breast cancer, including ER-positive/HER2 overexpressed tumors, attributed to the addition of targeted therapy, including hormonal agents and trastuzumab. However, no specific targeted agents are currently available for the treatment of TNBC. This review aims to collate and describe the most recent data on targeted therapies that have demonstrated efficacy in the management of metastatic TNBC. Targeted agents that have been investigated in the treatment of metastatic TNBC include inhibitors of poly(ADP-ribose) polymerase, angiogenesis, mammalian target of rapamycin, epidermal growth factor receptor, HDAC, Jak2, and Src. Several of these agents have shown considerable promise.",
keywords = "EGFR, Metastatic, PARP, Targeted agents, Triple-negative breast cancer, VEGFR",
author = "Soley Bayraktar and Stefan Gl{\"u}ck",
year = "2013",
month = "2",
day = "11",
doi = "10.1007/s10549-013-2421-5",
language = "English",
volume = "138",
pages = "21--35",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Molecularly targeted therapies for metastatic triple-negative breast cancer

AU - Bayraktar, Soley

AU - Glück, Stefan

PY - 2013/2/11

Y1 - 2013/2/11

N2 - Triple-negative breast cancer (TNBC) refers to a heterogeneous group of tumors that do not express the estrogen/progesterone-receptor (ER/PR), and human epidermal growth factor receptor-2 (HER2). TNBC is an aggressive histological subtype with limited treatment options and very poor prognosis following progression after standard chemotherapy regimens. There have been significant improvements in the outcome of other subtypes of breast cancer, including ER-positive/HER2 overexpressed tumors, attributed to the addition of targeted therapy, including hormonal agents and trastuzumab. However, no specific targeted agents are currently available for the treatment of TNBC. This review aims to collate and describe the most recent data on targeted therapies that have demonstrated efficacy in the management of metastatic TNBC. Targeted agents that have been investigated in the treatment of metastatic TNBC include inhibitors of poly(ADP-ribose) polymerase, angiogenesis, mammalian target of rapamycin, epidermal growth factor receptor, HDAC, Jak2, and Src. Several of these agents have shown considerable promise.

AB - Triple-negative breast cancer (TNBC) refers to a heterogeneous group of tumors that do not express the estrogen/progesterone-receptor (ER/PR), and human epidermal growth factor receptor-2 (HER2). TNBC is an aggressive histological subtype with limited treatment options and very poor prognosis following progression after standard chemotherapy regimens. There have been significant improvements in the outcome of other subtypes of breast cancer, including ER-positive/HER2 overexpressed tumors, attributed to the addition of targeted therapy, including hormonal agents and trastuzumab. However, no specific targeted agents are currently available for the treatment of TNBC. This review aims to collate and describe the most recent data on targeted therapies that have demonstrated efficacy in the management of metastatic TNBC. Targeted agents that have been investigated in the treatment of metastatic TNBC include inhibitors of poly(ADP-ribose) polymerase, angiogenesis, mammalian target of rapamycin, epidermal growth factor receptor, HDAC, Jak2, and Src. Several of these agents have shown considerable promise.

KW - EGFR

KW - Metastatic

KW - PARP

KW - Targeted agents

KW - Triple-negative breast cancer

KW - VEGFR

UR - http://www.scopus.com/inward/record.url?scp=84874653875&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874653875&partnerID=8YFLogxK

U2 - 10.1007/s10549-013-2421-5

DO - 10.1007/s10549-013-2421-5

M3 - Article

VL - 138

SP - 21

EP - 35

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -